Studies have shown that GPX3 activity, along with its protein and mRNA levels in the plasma, is significantly elevated in ACS patients compared to those with stable CAD and healthy controls, and these increased levels of GPX3 are associated with improved outcomes [75]. Here, GPX3 is linked to coronary artery disorder.